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 2 
Abstract 1 
Pseudomonas aeruginosa is a major cause of healthcare-associated infections and resistance 2 
among isolates is an increasing burden.  The study purpose was to describe national resistance 3 
rates for clinical P. aeruginosa respiratory and bloodstream cultures and the prevalence of 4 
multidrug-resistant (MDR) P. aeruginosa within the Veterans Affairs (VA).  MDR was defined as 5 
non-susceptibility to at least one drug in at least 3 of the following 5 categories: carbapenems, 6 
extended-spectrum cephalosporins, aminoglycosides, and piperacillin/tazobactam.  We reviewed 7 
24,562 P. aeruginosa respiratory and bloodstream isolates across 126 VA facilities between 2009 8 
to 2013.  Most isolates were collected from inpatient settings (82%).  Resistance was highest in 9 
fluoroquinolones (33%) and exceeded 20% for all classes assessed (carbapenems, extended-10 
spectrum cephalosporins, aminoglycosides, and piperacillin/tazobactam).  Resistance was higher 11 
in inpatient settings and in respiratory isolates. Prevalence of MDR was 20% overall (22% for 12 
inpatient isolates, 11% outpatient, 21% respiratory, 17% bloodstream).  Our findings are 13 
consistent with previous surveillance reports 14 
.  15 
 3 
Body of the Text 1 
Introduction 2 
Pseudomonas aeruginosa is a major cause of healthcare-associated infections.(1) P. aeruginosa 3 
is a leading cause of severe Gram-negative infections, including pneumonia and bloodstream 4 
infections, which are associated with high mortality rates.(2, 3)   Antimicrobial resistance and 5 
multidrug-resistance (MDR) among P. aeruginosa isolates collected from hospitalized patients 6 
are increasing and threaten the appropriate treatment of patients with severe infections.(4, 5)  P. 7 
aeruginosa is also an important cause of community-acquired pneumonia in patients with 8 
underlying lung disease, alcoholism and compromised immune function.(6-8)  However, 9 
surveillance of isolates from the community is less frequent than from healthcare settings and 10 
nationwide resistance rates in community setting are less well understood. 11 
 12 
The Veterans Affairs (VA) is the largest integrated healthcare system in the United States (US), 13 
providing care to approximately 9 million Veterans in 140 medical centers and 1200 outpatient 14 
clinics.  Clinical antimicrobial susceptibility data from VA electronic datasets support a nationwide 15 
description of P. aeruginosa resistance.(9)  The aim of this study was to assess national antibiotic 16 
resistance rates for clinical P. aeruginosa respiratory and bloodstream cultures, as well as 17 
determine the prevalence of MDR P. aeruginosa in the VA system. 18 
 19 
Methods 20 
We evaluated antimicrobial susceptibility from all VA hospitals, long-term care units and outpatient 21 
facilities in the United States.(9)   We included all P. aeruginosa blood and respiratory clinical 22 
cultures collected between January 1, 2009 to December 31, 2013 from patients aged 18 years 23 
or older. 24 
 25 
 4 
We defined antibiotic resistance per the CDC Antibiotic Resistance Patient Safety Atlas 1 
Phenotype Definitions.(10)  We included the first isolate per person, per facility, per month.(10)  2 
Antibiotic susceptibility was based on the reported microbiology results of the clinical culture.  As 3 
microbiology practices and susceptibility breakpoints are not standardized throughout the VA 4 
system, we applied the 2014 Clinical Laboratory Standards Institute (CLSI) breakpoints to 5 
determine non-susceptibility where numeric minimum inhibitory concentrations (MIC) data were 6 
available.(11) Where MIC values were not available, we used the reported textual interpretation 7 
(i.e., resistant [R], intermediate [I], or susceptible [S]).)(12)  In cases of duplicate (same patient, 8 
same isolate, same day), yet conflicting antimicrobial susceptibility results, we included the most 9 
resistant result (i.e., R > I > S).(12)      10 
 11 
We grouped individual antibiotic agents into five categories as follows:  extended-spectrum 12 
cephalosporins (ceftazidime and cefepime); fluoroquinolones (levofloxacin and ciprofloxacin); 13 
aminoglycosides (amikacin, gentamicin, and tobramycin); carbapenems (imipenem, meropenem, 14 
and doripenem), and piperacillin/tazobactam (piperacillin and piperacillin/tazobactam).(10) 15 
Resistance was defined as an isolate that was not susceptible, thus either intermediate or 16 
resistant, to at least one drug in that category.(10)    Multidrug-resistance (MDR) was defined as 17 
non-susceptibility to at least one drug in at least 3 of the 5 categories (extended-spectrum 18 
cephalosporins, aminoglycosides, carbapenems, and piperacillin/tazobactam).(10) 19 
 20 
We presented summary rates of antibiotic resistance for each of the five antibiotic categories 21 
assessed and prevalence of MDR among P. aeruginosa isolates.   Antibiotic resistance for each 22 
antibiotic category was calculated as the number of non-susceptible isolates divided by the total 23 
number of isolates tested.  Prevalence of MDR was calculated as the number of MDR isolates 24 
divided by the total number of isolates tested.   We presented overall rates of antibiotic resistance 25 
 5 
and MDR over the entire study period, and presented rates by treatment setting, source, and CDC 1 
region.   All analyses will be performed with SAS (SAS, Cary, NC, Version 9.2).  2 
 3 
Results 4 
We identified 24,562 P. aeruginosa isolates from 126 VA facilities over the 5-year study period; 5 
82% were from inpatient settings.  Most isolates were obtained from white (72%), male (97%), 6 
Veterans 65 years and older (59%).  Resistance was highest for fluoroquinolones (33%) and 7 
lowest for the piperacillin class (piperacillin/tazobactam and piperacillin, 21%; Table 1).  8 
Resistance to carbapenems, extended-spectrum cephalosporins, and aminoglycosides was 24-9 
25%.  Resistance was higher in inpatient settings (Table 1) and in respiratory isolates (Table 2). 10 
Prevalence of MDR was 20% overall (22% and 11% for inpatient and outpatient settings, 11 
respectively; and 21% and 17% for respiratory and bloodstream isolates, respectively). 12 
 13 
Among inpatient cultures, resistance rates were highest in the Pacific region (fluoroquinolones 14 
42%, carbapenems 35%, MDR 30%) and lowest in the Mountain (fluoroquinolones 27%, 15 
carbapenems 17%, MDR 14%) and New England regions (fluoroquinolones 27%, piperacillin 16 
class 17%, MDR 16%) (Figure 1). Outpatient resistance rates were highest in the Mid-Atlantic 17 
region  (fluoroquinolones 31%, carbapenems 22%, MDR 21%) and lowest in the New England 18 
(fluoroquinolones 20%, carbapenems 10%, MDR 6%) and West South Central regions 19 
(fluoroquinolones 17%, carbapenems 11%, MDR 7%) (Figure 2).  20 
  21 
Discussion 22 
Treatment of P. aeruginosa infections are challenging due to intrinsic resistance and ability to 23 
develop resistance to multiple antimicrobial classes.(13, 14)  These features limit treatment 24 
options and complicate selection of appropriate initial antibiotic treatment, which can have 25 
devastating consequences on patient outcomes.(14, 15)  We observed rates of resistance in 26 
 6 
excess of 20% for all antimicrobial classes assessed.  Our findings are similar to previous 1 
surveillance reports, and in some cases, resistance was higher in our study.(4, 5, 13) The most 2 
recent study of 7,452 P. aeruginosa isolates from 79 US medical centers between 2012 to 2014 3 
demonstrated non-susceptibility of 20% for piperacillin-tazobactam, 18% for meropenem, and 4 
16% for ceftazidime, compared to our findings of 24% resistance for piperacillin-tazobactam and 5 
piperacillin, 27% for carbapenem, and 27% for extended-spectrum cephalosporins.(13)  6 
 7 
Prior surveillance data suggests a trend towards stabilized or decreased antimicrobial resistance 8 
to several agents among P. aeruginosa isolates in the US.(13, 16)  Recent data from the VA 9 
system has demonstrated this trend in deceased antimicrobial resistance among P. aeruginosa 10 
isolates.(17)  We observed similar resistance rates among bloodstream isolates to those 11 
previously reported. We also found higher resistance rates among nosocomial isolates and 12 
variations in resistance rates by CDC region.(17)   13 
 14 
Overall, we demonstrated high rates of MDR among P. aeruginosa isolates (20%), with higher 15 
rates in the inpatient vs. outpatient setting (22% vs. 11% outpatient) and pulmonary vs. blood 16 
source (21% vs. 17% blood).  National surveillance data from 2000 to 2009, including 205,526 P. 17 
aeruginosa isolates from pneumonia and bloodstream infections, demonstrated prevalence rates 18 
of MDR among P. aeruginosa isolates similar to our findings (22% for pneumonia; 15% for 19 
bloodstream infections).(4)  Among bloodstream isolates in a recent VA study, there was a lower 20 
rate of MDR than we had observed.(17)  Differences in methods used to define MDR likely explain 21 
variations in reported MDR rates.   While we used the CDC Patient Atlas MDR definitions requiring 22 
non-susceptibility to at least one antibiotic in at least 3 different classes, the previous study 23 
required resistance to all antibiotics tested in at least 3 different classes.(17)   24 
 25 
Finally, our results from the outpatient setting are noteworthy.  None of the antimicrobial classes 26 
 7 
assessed provided greater than 10% anti-pseudomonal coverage and rates of MDR were 11% 1 
nationally (Table 1), exceeding 20% in the Mid Atlantic region (Figure 2).  Inappropriate initial 2 
empiric antimicrobial treatment is thus an important concern in the treatment of community-onset 3 
P. aeruginosa infections. Inappropriate initial empiric antimicrobial treatment is common 4 
inpatients with community-acquired P. aeruginosa bloodstream infections and those with 5 
pneumonia and it is associated with greater mortality.(18, 19)  While combination therapy remains 6 
controversial, it may be important approach to minimize inappropriate initial therapy, especially in 7 
regions with the highest resistance rates. 8 
 9 
Our findings add to previous work, highlighting antibiotic resistance among P. aeruginosa isolates 10 
nationally.  We demonstrated that resistance to five key and commonly used antimicrobial classes 11 
was high despite treatment setting, culture source, and region.  Due to the poor outcomes 12 
associated with inappropriate treatment of severe P. aeruginosa isolates, facilities should 13 
consider developing treatment pathways or policies, which potentially include use of combination 14 
therapy and/or newer antimicrobial options, for infections in which MDR organisms are suspected.  15 
Additionally, knowledge of specific risk factors for resistant and MDR P. aeruginosa isolates would 16 
be important to help clinicians better care for patients with infections due to resistant pathogens, 17 
and is an important next step to this work.  Finally, antimicrobial stewardship programs are 18 
mandated in the acute care setting in the VA, however increased efforts in the outpatient setting 19 
are warranted and urgently needed.(20) Increased assistance with antibiotic selection could help 20 
to manage these difficult to treat infections due resistant P. aeruginosa isolates and potentially 21 
improve patient outcomes. 22 
 23 
There are limitations to this observational, cross-sectional work.  The inclusion of all positive P. 24 
aeruginosa respiratory and blood cultures enabled us to describe ecological resistance in the VA 25 
system, however, we did not distinguish between colonization from true infection.  Additionally, 26 
 8 
there is the potential for misclassification of community-acquired isolates, as we did not assess 1 
healthcare contact prior to outpatient culture date.   Another limitation is that our definition of 2 
resistance was based on non-susceptibility.  Therefore, isolates that were intermediate met our 3 
definition of resistance, and as such we may have overestimated true resistance.  However, our 4 
definitions are consistent with those used by the CDC Patient Safety Atlas.(10)  There is 5 
heterogeneity among microbiology laboratories in the VA system and different testing methods 6 
among labs may have impacted our findings.  We applied CLSI susceptibility breakpoints where 7 
MIC data was available, however MIC data was not available for all isolates. In such cases we 8 
had to rely on the interpretation as provided by the testing microbiology laboratory.  Finally, the 9 
generalizability of the study population and results are limited to the VA, a fully integrated 10 
healthcare system consisting of largely older, white male patients.  11 
 12 
In summary, among nearly 25,000 clinical P. aeruginosa respiratory and bloodstream isolates, 13 
resistance to five key and commonly used antimicrobial classes (fluoroquinolones, carbapenems, 14 
extended-spectrum cephalosporins, aminoglycosides, and piperacillin group) exceeded 20% and 15 
20% of isolates were MDR.  Resistance was higher among isolates collected from the inpatient 16 
versus outpatient setting and from a respiratory source.   17 
18 
 9 
Acknowledgements.   1 
The views expressed are those of the authors and do not necessarily reflect the position or policy 2 
of the United States Department of Veterans Affairs.  This material is based upon work supported, 3 
in part, by the Office of Research and Development, Department of Veterans Affairs. 4 
 5 
Conflict of interest.   6 
Haley J. Morrill is supported in part by a Career Development Award, Department of Veterans 7 
Affairs, and has received research funding from Merck (Cubist). 8 
Aisling R. Caffrey has received research funding from Pfizer Inc and Merck (Cubist), and The 9 
Medicines Company. 10 
Lan Jiang has no conflicts. 11 
David Dosa is a Veteran’s Affairs government employee. He has received research funding 12 
through the VA, The West Foundation, and National Institutes of Aging. 13 
Leonard A. Mermel has served as a consultant for The Medicines Company and has received 14 
research support from BARD.  15 
Kerry L. LaPlante has received research funding, or acted as an advisor or consultant for 16 
BARD/Davol, Merck (Cubist), Ocean Spray, Allergan, Pfizer Inc, and The Medicines Company.   17 
  18 
 10 
References 1 
 2 
1. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance S. 2005. 3 
Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 4 
41:848-854. 5 
2. Hattemer A, Hauser A, Diaz M, Scheetz M, Shah N, Allen JP, Porhomayon J, El-6 
Solh AA. 2013. Bacterial and clinical characteristics of health care- and community-7 
acquired bloodstream infections due to Pseudomonas aeruginosa. Antimicrob Agents 8 
Chemother 57:3969-3975. 9 
3. Rodrigo-Troyano A, Sibila O. 2017. The respiratory threat posed by multidrug resistant 10 
Gram-negative bacteria. Respirology doi:10.1111/resp.13115. 11 
4. Zilberberg MD, Shorr AF. 2013. Prevalence of multidrug-resistant Pseudomonas 12 
aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from 13 
hospitalized patients with pneumonia and bloodstream infections in the United States 14 
from 2000 to 2009. J Hosp Med 8:559-563. 15 
5. Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Antimicrobial susceptibility of 16 
Gram-negative organisms isolated from patients hospitalised with pneumonia in US and 17 
European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 18 
2009-2012. Int J Antimicrob Agents 43:328-334. 19 
6. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. 2008. A comparative study 20 
of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 21 
133:610-617. 22 
7. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A. 23 
2002. Community-acquired pneumonia due to gram-negative bacteria and 24 
pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 162:1849-25 
1858. 26 
8. Prina E, Ranzani OT, Polverino E, Cilloniz C, Ferrer M, Fernandez L, Puig de la 27 
Bellacasa J, Menendez R, Mensa J, Torres A. 2015. Risk factors associated with 28 
potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am 29 
Thorac Soc 12:153-160. 30 
9. Department of Veterans Affairs. Department of Veterans Affairs Statistics at a Glance. 31 
http://www.va.gov/vetdata/docs/Quickfacts/Stats_at_a_glance_08_27_15.pdf Last 32 
updated: 06/30/2015. Accessed: 03/17/2016. 33 
10. Centers for Disease Control and Prevention. Antibiotic Resistance Patient Safety 34 
Atlas. Phenotype Definitions.  Accessed April 13, 2016. Available at 35 
"http://gis.cdc.gov/grasp/PSA/Downloads/ARPatientSafetyAtlas-36 
PhenotypeDefinitions.pdf". 37 
11. Clinical Laboratory Standards Institute (CLSI). January 2015. CLSI document M100-38 
S25, . Performace Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth 39 
Informational Supplement. 40 
 11 
12. Centers for Disease Control and Prevention (CDC). National Healthcare Safety 1 
Network (NHSN). January 2014. Available at: 2 
http://www.cdc.gov/nhsn/PDFs/pscManual/11pscAURcurrent.pdf (accessed November 3 
2014). Antimicrobial Use and Resistance (AUR) Module. 4 
13. Sader HS, Huband MD, Castanheira M, Flamm RK. 2017. Pseudomonas aeruginosa 5 
Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International 6 
Network for Optimal Resistance Monitoring Program in the United States. Antimicrob 7 
Agents Chemother 61. 8 
14. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas 9 
aeruginosa: clinical impact and complex regulation of chromosomally encoded 10 
resistance mechanisms. Clin Microbiol Rev 22:582-610. 11 
15. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. 2005. 12 
Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial 13 
antimicrobial treatment. Antimicrob Agents Chemother 49:1306-1311. 14 
16. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, 15 
Sievert DM. 2016. Antimicrobial-Resistant Pathogens Associated With Healthcare-16 
Associated Infections: Summary of Data Reported to the National Healthcare Safety 17 
Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control 18 
Hosp Epidemiol doi:10.1017/ice.2016.174:1-14. 19 
17. Gentry CA, Williams RJ, 2nd. 2015. Increased antimicrobial susceptibility rates for 20 
Pseudomonas aeruginosa bloodstream isolates across the Veterans Affairs Healthcare 21 
System. Diagn Microbiol Infect Dis 82:215-221. 22 
18. Cheong HS, Kang CI, Wi YM, Ko KS, Chung DR, Lee NY, Song JH, Peck KR. 2008. 23 
Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with 24 
community-onset Pseudomonas aeruginosa bacteraemia. Eur J Clin Microbiol Infect Dis 25 
27:1219-1225. 26 
19. Cilloniz C, Gabarrus A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, 27 
Niederman MS, Torres A. 2016. Community-Acquired Pneumonia Due to Multidrug- 28 
and Non-Multidrug-Resistant Pseudomonas aeruginosa. Chest 150:415-425. 29 
20. Department of Veterans Affairs. January 2014. Available at: 30 
http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2964 (accessed May 31 
2014). Antimicrobial Stewardship Programs (ASP) (VHA Directive 1031). 32 
  33 
 12 
Table 1. Antibiotic Resistance Rates for Pseudomonas aeruginosa Respiratory and Blood 1 
Cultures among Veterans Affairs Inpatient and Outpatient Facilities by Treatment Setting 2 
from 2009 to 2013 3 
 Setting 
Antibiotic Category Overall Inpatient Outpatient 
Fluoroquinolones 
33 
(23,938) 
36 
(19,634) 
23 
(4,304) 
Carbapenems 
25 
(21,176) 
27 
  (17,424) 
15 
(3,752) 
Extended-spectrum cephalosporins 
25 
(24,068) 
27 
(19,758) 
15 
(4,310) 
Aminoglycosides 
24 
(24,514) 
25 
 (20,094) 
21 
(4,420) 
Piperacillin/ piperacillin/tazobactam 
21 
(21,529) 
24 
 (17,741) 
10 
(3,788) 
MDR per CDC definitions 
20 
(24,562) 
22 
(20,134) 
11 
(4,428) 
Total Number of Isolates 24,562 20,134 4,428 
CDC= Centers for Disease Control and Prevention; MDR= Multidrug resistant  4 
Data are % non-susceptible (number of isolates tested)  5 
 6 
Extended-spectrum cephalosporins category included ceftazidime and cefepime. 7 
Fluoroquinolones category included levofloxacin and ciprofloxacin. 8 
Aminoglycosides category included amikacin, gentamicin, and tobramycin. 9 
Carbapenems category included imipenem, meropenem, and doripenem. 10 
Piperacillins included piperacillin and piperacillin/tazobactam. 11 
CDC MDR was defined as non-susceptibility to at least one agent in at least three of the 12 
following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins, 13 
fluoroquinolones, and piperacillins. 14 
  15 
 13 
Table 2. Pseudomonas aeruginosa Antibiotic Resistance Rates for Respiratory and Blood 1 
Cultures among Veterans Affairs Facilities Nationally by Culture Source from 2009 to 2 
2013 3 
 Source 
Antibiotic Category Overall Lung  Blood 
Fluoroquinolones 
33 
(23,938) 
34 
(20.493) 
28 
(3,445) 
Carbapenems 
25 
(21,176) 
25 
  (18,089) 
20.8 
(3,087) 
Extended-spectrum cephalosporins 
25 
(24,068) 
25 
(20,594) 
21 
(3,474) 
Aminoglycosides 
24 
(24,514) 
25 
 (20.988) 
18 
(3,526) 
Piperacillins 
21 
(21,529) 
22 
 (18,416) 
18 
(3,113) 
MDR per CDC definitions 
20 
(24,562) 
21 
(21,031) 
17 
(3,531) 
Total Number of Isolates 24,562 21,031 3,531 
CDC= Centers for Disease Control and Prevention; MDR= Multidrug resistant  4 
Data are % non-susceptible (number of isolates tested)  5 
 6 
Extended-spectrum cephalosporins category included ceftazidime and cefepime. 7 
Fluoroquinolones category included levofloxacin and ciprofloxacin. 8 
Aminoglycosides category included amikacin, gentamicin, and tobramycin. 9 
Carbapenems category included imipenem, meropenem, and doripenem. 10 
Piperacillins included piperacillin and piperacillin/tazobactam. 11 
CDC MDR was defined as non-susceptibility to at least one agent in at least three of the 12 
following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins, 13 
fluoroquinolones, and piperacillins. 14 
  15 
 14 
Figure 1.  Pseudomonas aeruginosa Antibiotic Resistance Among Veterans Affairs 1 
Inpatient Facilities by CDC Region 2 
 3 
 4 
 5 
AMG= Aminoglycosides; CDC= Centers for Disease Control and Prevention; E N Central= East 6 
North Central Region; E S Central= East South Central Region; ES Ceph= Extended-spectrum 7 
cephalosporin; FQ= Fluoroquinolone; MDR= Multidrug resistant; Mid Atlantic= Middle Atlantic 8 
Region; Mountain=Mountain Region; New England= New England Region; Pacific= Pacific 9 
Region; PIP= Piperacillins; S Atlantic= South Atlantic Region; W N Central= West North Central 10 
Region; W S Central= West South Central Region 11 
 12 
Data are % non-susceptible (total number of isolates tested). Not every antibiotic category tested 13 
for every isolate tested.  14 
 15 
Extended-spectrum cephalosporins category included ceftazidime and cefepime. 16 
Fluoroquinolones category included levofloxacin and ciprofloxacin. 17 
Aminoglycosides category included amikacin, gentamicin, and tobramycin. 18 
Carbapenems category included imipenem, meropenem, and doripenem. 19 
Piperacillins included piperacillin and piperacillin/tazobactam. 20 
CDC MDR was defined as non-susceptibility to at least one agent in at least three of the 21 
following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins, 22 
fluoroquinolones, and piperacillins. 23 
  24 
 15 
Figure 2.  Pseudomonas aeruginosa Antibiotic Resistance Among Veterans Affairs 1 
Outpatient Facilities by CDC Region 2 
 3 
 4 
 5 
AMG= Aminoglycosides; CDC= Centers for Disease Control and Prevention; E N Central= East 6 
North Central Region; E S Central= East South Central Region; ES Ceph= Extended-spectrum 7 
cephalosporin; FQ= Fluoroquinolone; MDR= Multidrug resistant; Mid Atlantic= Middle Atlantic 8 
Region; Mountain=Mountain Region; New England= New England Region; Pacific= Pacific 9 
Region; PIP= Piperacillins; S Atlantic= South Atlantic Region; W N Central= West North Central 10 
Region; W S Central= West South Central Region 11 
 12 
Data are % non-susceptible (total number of isolates tested). Not every antibiotic category tested 13 
for every isolate tested.  14 
 15 
Extended-spectrum cephalosporins category included ceftazidime and cefepime. 16 
Fluoroquinolones category included levofloxacin and ciprofloxacin. 17 
Aminoglycosides category included amikacin, gentamicin, and tobramycin. 18 
Carbapenems category included imipenem, meropenem, and doripenem. 19 
Piperacillins included piperacillin and piperacillin/tazobactam. 20 
CDC MDR was defined as non-susceptibility to at least one agent in at least three of the 21 
following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins, 22 
fluoroquinolones, and piperacillins. 23 
 24 
